Capsule endoscopy (CE), introduced in 2000 and FDA-approved in 2001, remains a valuable tool for diagnosing gastrointestinal (GI) lesions, particularly in areas inaccessible to traditional endoscopy. While CE offers non-invasive imaging and improves detection of small bowel diseases and obscure GI bleeding, its widespread use is hindered by limitations such as lack of therapeutic capabilities, inability to obtain biopsies, reliance on peristalsis for movement, and time-consuming image interpretation.
Trending
- Private equity owns less than 4% of U.S. hospitals, study finds (Medical Xpress)
- FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help? (HCP Live)
- Greg O’Grady: The Surgeon Who Left Surgery to Map the Stomach (Gut Health Times)
- GI Practices Lose More on Second Procedures Than Any Other Specialty, Jiro Health Benchmark Finds (PR Newswire)
- Throne Announces First Clinical Validation Study, Demonstrating Its AI-Powered Stool Classification Performs Comparably to Board-Certified Gastroenterologists (Business Wire)
- Blood-Based Colorectal Cancer Screening Averts More Deaths Than Stool Tests, Modeling Shows (Clinical Lab Products)
- For Better or Worse, Monitored Anesthesia Care Is Now the Default in GI Endoscopy (GI & Endoscopy News)
- AI ‘may offer an efficient way’ to detect colorectal neoplasia, but more research needed (Healio)
